Compare Incyte Corporation (INCY) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Vital Farms Inc — how do they compare? Incyte Corporation trades at $115.71 (market cap $23.11B), while Vital Farms Inc trades at $13.78 (market cap $590.45M). The key difference: Incyte Corporation is far larger — about 39.1× Vital Farms Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Vital Farms Inc nearer its low. Which is the better fit depends on your goals.
| INCY | VITL | |
|---|---|---|
Market Cap | $23.11B | $590.45M |
Sector | Health | Consumer Staples |
52-Week High | $118.52 | $52.41 |
52-Week Low | $67.38 | $8.28 |
Enterprise Value | $19.13B | $593.26M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Vital Farms (VITL) trades at $13.76, up 1.55% with a bullish technical signal from moving averages. The company shows solid profitability with 6.1% net margin and 15.44% ROE, though recent earnings missed expectations in two of the last three quarters. Analyst consensus is positive with 56% buy ratings and a $13.50 price target, while news highlights declining short interest and ongoing class action lawsuits.
The stock presents a mixed outlook with strong fundamentals offset by legal risks and earnings volatility. Valuation appears reasonable with P/E of 13.02 and P/S of 0.79, but investors should weigh the class action litigation's potential impact against the company's operational strength in the natural foods sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
